456 related articles for article (PubMed ID: 23244114)
1. Clinical characteristics and survival analysis of breast cancer molecular subtypes with hepatic metastases.
Ge QD; Lv N; Kong YN; Xie XH; He N; Xie XM; Wei WD
Asian Pac J Cancer Prev; 2012; 13(10):5081-6. PubMed ID: 23244114
[TBL] [Abstract][Full Text] [Related]
2. Clinical features and survival analysis of different subtypes of patients with breast cancer brain metastases.
Bai B; Yuan ZY; Liu DG; Teng XY; Wang SS
Chin J Cancer; 2010 Apr; 29(4):413-9. PubMed ID: 20346218
[TBL] [Abstract][Full Text] [Related]
3. Hepatic resection for breast cancer liver metastases: Impact of intrinsic subtypes.
Chun YS; Mizuno T; Cloyd JM; Ha MJ; Omichi K; Tzeng CD; Aloia TA; Ueno NT; Kuerer HM; Barcenas CH; Vauthey JN
Eur J Surg Oncol; 2020 Sep; 46(9):1588-1595. PubMed ID: 32253074
[TBL] [Abstract][Full Text] [Related]
4. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study.
Li X; Zhang X; Liu J; Shen Y
BMC Cancer; 2020 Nov; 20(1):1102. PubMed ID: 33187507
[TBL] [Abstract][Full Text] [Related]
5. Relative and disease-free survival for breast cancer in relation to subtype: a population-based study.
Minicozzi P; Bella F; Toss A; Giacomin A; Fusco M; Zarcone M; Tumino R; Falcini F; Cesaraccio R; Candela G; La Rosa F; Federico M; Sant M
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1569-77. PubMed ID: 23892409
[TBL] [Abstract][Full Text] [Related]
6. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients.
Arslan UY; Turker I; Aksoy S; Oksuzoglu B; Helvaci K; Yildirim Ozdemir N; Uyeturk U; Uysal Sonmez O; Budakoglu B; Zengin N
J BUON; 2013; 18(3):585-93. PubMed ID: 24065468
[TBL] [Abstract][Full Text] [Related]
7. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes.
Kos T; Aksoy S; Sendur MA; Arik Z; Civelek B; Kandemir N; Ozdemir NY; Zengin N; Altundag K
J BUON; 2013; 18(3):608-13. PubMed ID: 24065471
[TBL] [Abstract][Full Text] [Related]
8. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
9. Specific sites of metastases in invasive lobular carcinoma: a retrospective cohort study of metastatic breast cancer.
Inoue M; Nakagomi H; Nakada H; Furuya K; Ikegame K; Watanabe H; Omata M; Oyama T
Breast Cancer; 2017 Sep; 24(5):667-672. PubMed ID: 28108967
[TBL] [Abstract][Full Text] [Related]
10. A study of high-nuclear-grade breast cancer in Thailand: subclassification and correlation with prognostic factors and immunohistochemical study.
Chaiwun B; Nakrungsee S; Sukhamwang N; Srisukho S
Breast Cancer; 2010; 17(1):35-41. PubMed ID: 19789946
[TBL] [Abstract][Full Text] [Related]
11. Male breast cancer: immunohistochemical subtypes and clinical outcome characterization.
Sánchez-Muñoz A; Román-Jobacho A; Pérez-Villa L; Sánchez-Rovira P; Miramón J; Pérez D; Sáez MI; de Luque V; Medina L; Ramírez-Tortosa CL; Vicioso L; Medina JA; Ribelles N; Alba E
Oncology; 2012; 83(4):228-33. PubMed ID: 22907070
[TBL] [Abstract][Full Text] [Related]
12. The clinicopathological evaluation of the breast cancer patients with brain metastases: predictors of survival.
Tarhan MO; Demir L; Somali I; Yigit S; Erten C; Alacacioglu A; Ellidokuz H; Seseogullari O; Kucukzeybek Y; Can A; Dirican A; Bayoglu V; Akyol M
Clin Exp Metastasis; 2013 Feb; 30(2):201-13. PubMed ID: 22915160
[TBL] [Abstract][Full Text] [Related]
13. St Gallen molecular subtypes in primary breast cancer and matched lymph node metastases--aspects on distribution and prognosis for patients with luminal A tumours: results from a prospective randomised trial.
Falck AK; Fernö M; Bendahl PO; Rydén L
BMC Cancer; 2013 Nov; 13():558. PubMed ID: 24274821
[TBL] [Abstract][Full Text] [Related]
14. [Clinical features and prognosis analysis of different breast cancer molecular subtypes].
Yang Q; Chen J; Li HJ; Yu M; Tian CX; Lü Q
Zhonghua Zhong Liu Za Zhi; 2011 Jan; 33(1):42-6. PubMed ID: 21575463
[TBL] [Abstract][Full Text] [Related]
15. Treatment outcomes and prognostic factors for patients with brain metastases from breast cancer of each subtype: a multicenter retrospective analysis.
Niikura N; Hayashi N; Masuda N; Takashima S; Nakamura R; Watanabe K; Kanbayashi C; Ishida M; Hozumi Y; Tsuneizumi M; Kondo N; Naito Y; Honda Y; Matsui A; Fujisawa T; Oshitanai R; Yasojima H; Tokuda Y; Saji S; Iwata H
Breast Cancer Res Treat; 2014 Aug; 147(1):103-12. PubMed ID: 25106661
[TBL] [Abstract][Full Text] [Related]
16. Om.breast cancer in very young women aged 25 year-old or below in the center of Tunisia and review of the literature.
Ben Abdelkrim S; Fathallah K; Rouatbi R; Ayachi M; Hmissa S; Mokni M
Pathol Oncol Res; 2015 Jul; 21(3):553-61. PubMed ID: 25962349
[TBL] [Abstract][Full Text] [Related]
17. Risk factors and survival outcome in cerebral metastatic breast cancer.
Bachmann C; Schmidt S; Staebler A; Schittenhelm J; Wallwiener D; Grischke EM
Med Oncol; 2014 Mar; 31(3):862. PubMed ID: 24504842
[TBL] [Abstract][Full Text] [Related]
18. Risk and prognostic factors of breast cancer with liver metastases.
Ji L; Cheng L; Zhu X; Gao Y; Fan L; Wang Z
BMC Cancer; 2021 Mar; 21(1):238. PubMed ID: 33676449
[TBL] [Abstract][Full Text] [Related]
19. Retrospective analysis of risk factors for central nervous system metastases in operable breast cancer: effects of biologic subtype and Ki67 overexpression on survival.
Ishihara M; Mukai H; Nagai S; Onozawa M; Nihei K; Shimada T; Wada N
Oncology; 2013; 84(3):135-40. PubMed ID: 23235554
[TBL] [Abstract][Full Text] [Related]
20. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]